Marcaina (Bupivacaine Hydrochloride)

Bupivacaine blocks voltage‑gated sodium channels on nerve membranes, preventing sodium influx that is essential for depolarization. By inhibiting nerve impulse propagation, it produces a reversible loss of sensation in the area where it is applied, without affecting the patient's level of consciousness.

The specific dose of Marcaina is determined by the prescribing clinician based on the intended procedure, patient characteristics, and route of administration. Healthcare professionals calculate the appropriate amount to achieve effective anesthesia while minimizing the risk of toxicity.

Safety data for bupivacaine in pregnancy and lactation are limited. Use of Marcaina during pregnancy or while breastfeeding should only occur when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be prescribed by a qualified healthcare provider.

To order Marcaina, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain if needed) and assists with any required import documentation.

Compared with shorter‑acting agents such as lidocaine, bupivacaine offers a longer duration of anesthesia and analgesia, making it suitable for procedures requiring extended pain control. However, its higher potency also demands careful dosing and monitoring to avoid systemic toxicity.

Marcaina should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Ensure the container is tightly sealed and avoid exposure to extreme temperatures to maintain product stability.

Marcaina is administered by a qualified healthcare professional via epidural injection or infiltration into the targeted tissue. The route and technique are selected based on the clinical indication, and the drug is typically delivered as a sterile solution using appropriate aseptic methods.

Serious risks include cardiovascular toxicity such as arrhythmias or cardiac arrest, and central nervous system toxicity manifesting as seizures or loss of consciousness. Prompt recognition and management of these events are essential, and resuscitation equipment should be readily available during administration.

Marcaina should be avoided in patients with known hypersensitivity to amide‑type local anesthetics, those with severe cardiac conduction disorders, or individuals with uncontrolled epilepsy. Caution is also advised for patients with significant hepatic impairment or those receiving interacting medications that affect cardiac or CNS function.